19 June 2013
Keywords: atherogenics, sees, fy, income, 32m, pharmaceutical, company
Article | 05 March 2007
AtheroGenics, a US pharmaceutical company focused on drugs for chronic inflammatory diseases, reported total revenue of $11.0 million for the
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 March 2007
18 June 2013
© 2013 thepharmaletter.com